Hirudin

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Polypeptide derived from the leech Hirudo medicinalis officinalis, which is used for anticoagulation. Hirudin itself is only synthesized by leeches, whereas genetically engineered recombinant hirudin analogues, e.g. lepirudin, are used in pharmaceuticals.

Half-lifeThis section has been translated automatically.

4 hours

Pharmacodynamics (Effect)This section has been translated automatically.

Direct inhibitor of the coagulation factor thrombin. Binds to its catalytic centres and prevents the conversion of fibrinogen to fibrin. In addition, the coagulation factors V, VII and XIII are inactivated.

IndicationThis section has been translated automatically.

Undesirable effectsThis section has been translated automatically.

Known are allergic ADRs, which are classified as type I and type IV sensitisations.

PreparationsThis section has been translated automatically.

S.u. Lepirudin.

Note(s)This section has been translated automatically.

In 1884, the British physiologist John Berry Haycraft discovered that leeches secrete a substance with a strong anticoagulant effect when sucking blood, which he called hirudin.

LiteratureThis section has been translated automatically.

  1. Lewis BE et al (2007) Direct thrombin inhibition during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Expert Rev Cardiovasc Ther 5: 57-68

Authors

Last updated on: 29.10.2020